ClinicalTrials.gg
CompletedNCT04335266Updated Apr 6, 2020

A Food Effect Study of SHR2554 on Healthy Chinese Male Adult Subjects

A Phase 1 interventional study of SHR2554 in Healthy Adult Subjects, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to male participants aged 40 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-04-06.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Aug 2019, registered Apr 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
40 Years to 60 Years
Sex
Male
01

Study summary

The primary objective of the study is to evaluate the effect of high-fat diet on pharmacokinetics of healthy Chinese male adult subjects after oral administration of SHR2554 tablets.

The secondary objective of the study is to evaluate the safety of single dose of SHR2554 orally in healthy subjects.

02

Conditions studied

  • Healthy Adult Subjects
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male subjects aged 40\~60 at the date of signing the ;
  2. Male body weight ≥ 50kg , (BMI) within the range of 19 \~ 28kg /m2 (including 19 and 28) (BMI= weight (kg)/height 2 (m2));
  3. During screening period physical examination, vital signs, blood routine, urine routine, blood biochemistry, coagulation, abdominal ultrasound, chest X-ray and other examination results must be within the normal range consistent with age and gender, or in accordance with the protocol, or judged to be "no clinical significance (NCS)" if beyond the normal range;
  4. Agree to abstain from sex or use effective non-drug from screening to at least 3 months after the last study drug administration (female subjects are also required to abstain or use effective non-drug contraceptives two weeks prior to study entry);
  5. The subject can communicate well with the researcher, understand and comply with the requirements of the study, understand and sign the informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Allergic constitution or known allergy to the research drug/similar drugs;
  2. Frequent use of sedatives, sleeping pills or other addictive drugs; History of drug abuse within 6 months prior to first administration or drug abuse screening positive; Alcoholic or often drinkers within 6 months prior to screening, the average drinking amount is more than 14 units a week (1 unit= 285 ml beer or 25 ml alcohol content of 40% spirits or 100 ml wine), a heavy smoker or quitting time less than 3 months, alcohol breath test positive and nicotine test positive, and can't quit smoking and alcohol during the study;
  3. A history of cardiovascular diseases such as myocarditis, coronary heart disease, pathological arrhythmia and stroke;
  4. Pulmonary diseases, including invasive lung disease, pneumonia, and dyspnoea;
  5. Chronic kidney disease, renal insufficiency, renal anaemia;
  6. A history of dysphagia or any gastrointestinal disease affecting drug absorption;
  7. Any uncontrolled peptic ulcer, colitis, pancreatitis, etc;
  8. Any operation within the previous 3 months that may affect the absorption, distribution, metabolism and excretion of drugs;
  9. Previous medical history of cardiovascular, liver, kidney, lung, digestive tract, nervous system diseases, etc., which may significantly affect the absorption, distribution, metabolism and excretion of drugs, or may pose a hazard to the subjects participating in the study. The following medical history or conditions should be considered: inflammatory gastroenteritis, gastroesophageal reflux, gastrointestinal or rectal bleeding; History of pancreatic injury or pancreatitis; Greater surgical history such as gastrectomy, gastroenterostomy, or enterectomy; History of acute and chronic renal insufficiency, history of renal transplantation;
  10. Taking any hepatotoxic drugs (such as dapsone, erythromycin, fluconazole, ketoconazole and rifampicin) in the months prior to screening;
  11. hose who have participated in other clinical trials and taken the research drugs within 3 months before the first drug administration;
  12. Any drug that altered the activity of liver enzymes was given 28 days prior to administration or during the study;
  13. Use any prescription drug or herbal tonic within one week before the first dose;
  14. Use any over-the-counter (OTC) or food supplement (including vitamins, calcium tablets, etc.) within one weeks before the first dose;
  15. Clinical laboratory examination is abnormal and to be CS;
  16. surface antigen positive, hepatitis C2 antibody positive, syphilis antibody positive, antibody positive;
  17. Subjects refused to stop using any beverage or food containing methyl xanthine, such as coffee, tea, cola, chocolate, etc. from 48 hours before the first administration until the end of the study;
  18. Blood donation within 3 months before the screening or blood loss great than 400 mL;
  19. Difficulty in venous blood collection or inability to tolerate venepuncture;
  20. Other factors (including but not limited to inability to understand the requirements of the study, poor compliance, physical weakness, etc.) that are not suitable for participating in the study, as judged by the researcher.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Treatment group A

    Drug: SHR2554 fasted in P1, high-fat diet in P2 SHR2554 administration in fasted condition in period 1, SHR2554 administration after high-fat diet in period 2

    Drug: SHR2554

  • Experimental
    Treatment group B

    Drug: SHR2554 high-fat diet in P1, fasted in P2 SHR2554 administration after high-fat diet in period 1, SHR2554 administration in fasted condition in period 2

    Drug: SHR2554

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics parameter: Cmax of SHR2554

    Peak Plasma Concentration (Cmax) of SHR2554

    Time frame: Day 1 and Day 8 of the single dose

  2. Pharmacokinetics parameter: AUC of SHR2554

    Area under the plasma concentration versus time curve (AUC) of SHR2554

    Time frame: Day 1 and Day 8 of the single dose

07

Study locations

1 site
  • Henan Cancer Hospital
    Henan, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Sep 2019, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2020
First posted
Apr 6, 2020
StartActual
Aug 6, 2019
Primary completionActual
Sep 9, 2019
CompletionActual
Mar 30, 2020
Last update
Apr 6, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04335266
Responsible party
Sponsor
First posted
Apr 6, 2020
Start date
Aug 6, 2019
Primary completion
Sep 9, 2019
Completion
Mar 30, 2020
Last update
Apr 6, 2020

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zeprumetostat

Start the discussion